ABBVIE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 159 EUR | +0.94% |
|
-0.44% | +14.22% |
| 06-28 | Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU | MT |
| 06-28 | AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment | MT |
| Sales 2024 * | 55.2B 51.53B 4,366B | Sales 2025 * | 58.19B 54.33B 4,603B | Capitalization | 303B 283B 23,956B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.6B 8.03B 681B | Net income 2025 * | 11.44B 10.68B 904B | EV / Sales 2024 * | 6.52 x |
| Net Debt 2024 * | 56.89B 53.11B 4,500B | Net Debt 2025 * | 47.91B 44.73B 3,789B | EV / Sales 2025 * | 6.03 x |
| P/E ratio 2024 * |
29.9
x | P/E ratio 2025 * |
23.5
x | Employees | 50,000 |
| Yield 2024 * |
3.63% | Yield 2025 * |
3.79% | Free-Float | 96.38% |
More Fundamentals
* Assessed data
More news
Latest transcript on AbbVie Inc.
More recommendations
More press releases
| 1 day | +0.94% | ||
| 1 week | -0.44% | ||
| Current month | +9.46% | ||
| 1 month | +12.13% | ||
| 3 months | -5.24% | ||
| 6 months | +14.55% | ||
| Current year | +14.22% |
1 week
157.52
162.20
1 month
142.20162.20
Current year
141.40168.80
1 year
119.00168.80
3 years
89.89168.80
5 years
56.00168.80
10 years
37.79168.80
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 31/12/12 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 31/12/12 |
Robert Michael
PSD | President | 53 | 31/12/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 31/12/12 |
Edward Rapp
BRD | Director/Board Member | 66 | 31/12/12 |
| Director/Board Member | 70 | 31/12/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/06/24 | 159 | +0.94% | 514 |
| 27/06/24 | 157.5 | -2.14% | 11 |
| 26/06/24 | 161 | +0.60% | 48 |
| 25/06/24 | 160 | -0.40% | 793 |
| 24/06/24 | 160.6 | +0.59% | 1,132 |
Delayed Quote Deutsche Boerse AG, June 28, 2024 at 10:41 am
More quotes
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
Pharmaceuticals
Calendar
14/07/2024
- Détachement de
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
171.5
USD
Average target price
183.2
USD
Spread / Average Target
+6.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.32% | 815B | |
| +44.05% | 641B | |
| -6.75% | 352B | |
| +13.56% | 314B | |
| +16.57% | 242B | |
| +13.31% | 218B | |
| +8.48% | 168B | |
| -2.81% | 159B | |
| +0.20% | 120B |
- Stock Market
- Equities
- ABBV Stock
- 4AB Stock
